zevtera 500 mg pulver till koncentrat till infusionsvätska, lösning
basilea pharmaceutica deutschland gmbh - ceftobiprolmedokarilnatrium - pulver till koncentrat till infusionsvätska, lösning - 500 mg - ceftobiprolmedokarilnatrium 666,6 mg aktiv substans - ceftobiprolmedokaril
melphalan amring 50 mg pulver och vätska till injektions-/infusionsvätska, lösning
amring farma srl - melfalanhydroklorid - pulver och vätska till injektions-/infusionsvätska, lösning - 50 mg - melfalanhydroklorid 55,97 mg aktiv substans; etanol, vattenfri hjälpämne; propylenglykol hjälpämne
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastiska medel - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
rhesonativ 750 ie/ml injektionsvätska, lösning
octapharma ab - anti-d immunglobulin, humant - injektionsvätska, lösning - 750 ie/ml - anti-d immunglobulin, humant 750 ie aktiv substans
gammanorm 165 mg/ml injektionsvätska, lösning
octapharma ab - immunglobulin, humant normalt - injektionsvätska, lösning - 165 mg/ml - immunglobulin, humant normalt 165 mg aktiv substans - normalt immunglobulin för extravaskulärt bruk
venbig 50 ie/ml pulver och vätska till infusionsvätska, lösning
kedrion s.p.a - anti-hepatit b-immunglobulin, humant - pulver och vätska till infusionsvätska, lösning - 50 ie/ml - sackaros hjälpämne; anti-hepatit b-immunglobulin, humant 50 ie aktiv substans - immunglobulin mot hepatit b
neohepatect 50 ie/ml infusionsvätska, lösning
biotest pharma gmbh - anti-hepatit b-immunglobulin, humant - infusionsvätska, lösning - 50 ie/ml - anti-hepatit b-immunglobulin, humant 50 ie aktiv substans - immunglobulin mot hepatit b
intratect 100 g/l infusionsvätska, lösning
biotest pharma gmbh - immunglobulin, humant normalt, för intravenös administrering - infusionsvätska, lösning - 100 g/l - immunglobulin, humant normalt, för intravenös administrering 100 g aktiv substans - normalt immunglobulin för intravaskulärt bruk
intratect 50 g/l infusionsvätska, lösning
biotest pharma gmbh - immunglobulin, humant normalt, för intravenös administrering - infusionsvätska, lösning - 50 g/l - immunglobulin, humant normalt, för intravenös administrering 50 g aktiv substans - normalt immunglobulin för intravaskulärt bruk